Key Highlights
- Third quarter net loss was USD 128 million, or USD 1.00 per share, compared with USD 135 million, or USD 1.27 per share, a year earlier.
- Revenue fell to USD 9 million from USD 26 million, while operating expenses dropped to USD 140 million from USD 168 million.
- Cash, cash equivalents and marketable securities were USD 694 million at September 30, 2026, before an October offering of 16.4 million shares at USD 17.50.
- Management says cash plus the October proceeds should fund planned operations into 2029, but substantial additional funding will still be needed.
Revenue Slides While Spending Eases
Arcus Biosciences (NYSE:RCUS), a late clinical-stage biopharmaceutical company focused on cancer and immunology, filed its Quarterly Report on November 4, 2026 for the period ended September 30, 2026. Revenue was USD 9 million versus USD 26 million, and nine-month revenue was USD 67 million versus USD 214 million, which included USD 192 million of license and development services revenue in the 2025 period. Research and Development spending fell to USD 117 million from USD 141 million. The net loss for nine months widened to USD 347 million from USD 247 million. General and administrative expense was USD 23 million versus USD 27 million, and interest and other income fell to USD 6 million from USD 10 million. The company has no product sales, and all revenue to date has come from collaboration, license and research arrangements.
Why the Raise Came With a Large Cash Balance
In October 2026, the company sold 16.4 million shares at USD 17.50 in an underwritten offering, for gross proceeds of approximately USD 288 million before costs. Management says the cash at September 30, together with those proceeds, funds planned operations into 2029. Weighted shares rose to 127.4 million from 106.5 million. The filing explains that the company needs substantial additional funding to continue development and expects to rely on equity, Debt or partnerships. Gilead's option rights under the 2020 collaboration ended on July 14, 2026 after Gilead chose not to make the continuation payment. Of a USD 30 million milestone from Taiho, USD 15 million was received in the third quarter and USD 15 million is due in the first quarter of 2027.
Casdatifan Data and a Discontinued Phase 3 Study
In October 2026, Arcus Biosciences (NYSE:RCUS) reported casdatifan data in clear cell renal cell carcinoma. In first-line patients, casdatifan plus zimberelimab (30 patients) showed a 50% confirmed response rate. Casdatifan plus cabozantinib in 43 second-line patients showed median progression-free survival of 14.5 months and a 44% confirmed response rate. In 121 late-line patients on monotherapy, median overall survival was 35 months, median progression-free survival was 13 months and the response rate was 36%. These are early cohort results and not randomized comparisons. In August 2026, the company discontinued the Phase 3 PACIFIC-8 study of domvanalimab and terminated its agreement with AstraZeneca.
Where Things Stand
The company raised money while holding a large cash balance, which management links to funding development into 2029. Arcus Biosciences (NYSE:RCUS) reported a USD 128 million quarterly loss with revenue of just USD 9 million, so its funding depends on Equity markets and partners. The offering adds roughly USD 288 million gross, but dilutes existing holders. The key factors now are casdatifan trial progress and any new partner Economics after Gilead's option rights ended.




_11_13_2026_20_27_09_053340.jpg)

Please wait processing your request...